Drug intelligence / Profile preview

DMG-Am

Development stage: Preclinical
Lead developer: South-West University Neofit Rilski
Modality: Small Molecules

Overview

**DMG-Am** is an experimental N,N-dimethylglycine-amantadine compound developed by investigators at South-West University Neofit Rilski and the Bulgarian Academy of Sciences. It was synthesized as a potential adjunctive antiparkinsonian agent intended to combine the established N-methyl-D-aspartate receptor-antagonist activity associated with amantadine and the proposed antioxidant properties of N,N-dimethylglycine. In an MPTP-induced mouse model of Parkinson's disease, 12 days of treatment improved motor coordination and memory performance to control-like levels. DMG-Am has only been reported in preclinical academic research and has no established clinical use, approved indication, marketed formulation, or assigned INN.

Other names: N,N-dimethylglycine-amantadine

Beyond the preview

Go deeper on DMG-Am.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMG-Am.

Explore the full profile